Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status

Objective: Cancer ovary is one of the fatal gynecologic malignancies worldwide. Since breast cancer (BRCA) genes are considered tumor suppressor genes and play important roles in cancer by repairing of chromosomal damage with the error repair of DNA breaks. Therefore, breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) gene mutations strongly enhance the development of ovarian cancer risk among women. Here, we report that both genes are an essential mediator of progress ovarian cancer, to determine the influence of BRCA1 and BRCA2 mutations in the improvement of ovarian cancer.Methods: A total of 25 subjects were chosen for the genetic studies, and three groups were recruited: fifteen ovarian cancer patients group, five healthy controls, and five first-degree relatives to a known case of ovarian cancer patients.Results: A genetic analysis revealed that a strong correlation exists between both gene mutations’ status in ovarian cancer, and BRCA gene mutations (185delAG, 5382insC, and 4153delA in BRCA1 and 6174delT in BRCA2) remained to establish to have a relatively high frequency among people in this study among ovarian cancer patients. Furthermore, seven patients with ovarian cancer carried all of the four investigated mutations, and five had three mutations.Conclusion: Otherwise, BRCA gene frequency showed low prevalence among first-degree relatives, and to a lesser extent among healthy controls, with only a few had all of the mutations combined. These data demonstrate for the first time a molecular link between BRCA1 and BRCA2 mutations in ovarian cancer progression in Iraq.

Download Full-text

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

Women s Health ◽

10.1177/1745505717750694 ◽

2018 ◽

Vol 14 ◽

pp. 174550571775069 ◽

Cited By ~ 5

Author(s):

Maurie Markman

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Drug Administration ◽

Clinical Data ◽

Food And Drug Administration ◽

Gynecologic Oncology ◽

Brca Gene ◽

Polymerase Inhibitors ◽

The Us ◽

Relevant Role

There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and particularly (although not exclusively) in the setting of known mutations in the BRCA gene. This review will briefly highlight the biological rational for the use of poly (ADP-ribose) polymerase inhibitors in this malignancy, followed by summary of currently available clinical data supporting the delivery of agents approved by the US Food and Drug Administration for non-investigative use.

Download Full-text

Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.009 ◽

2019 ◽

Vol 154 (1) ◽

pp. 138-143 ◽

Cited By ~ 4

Author(s):

Federica Tomao ◽

Lucia Musacchio ◽

Federica Di Mauro ◽

Serena Maria Boccia ◽

Violante Di Donato ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Hematologic Toxicity ◽

High Grade ◽

Serous Ovarian Cancer ◽

Mutational Status ◽

Platinum Based Chemotherapy

Download Full-text

The N-Terminally Truncated p53 Isoform Δ40p53 Influences Prognosis in Mucinous Ovarian Cancer

International Journal of Gynecological Cancer ◽

10.1097/igc.0b013e31823ca031 ◽

2012 ◽

Vol 22 (3) ◽

pp. 372-379 ◽

Cited By ~ 24

Author(s):

Gerda Hofstetter ◽

Astrid Berger ◽

Regina Berger ◽

Arijana Zorić ◽

Elena I. Braicu ◽

...

Keyword(s):

Ovarian Cancer ◽

Confidence Interval ◽

Western Blot ◽

Blot Analysis ◽

Western Blot Analysis ◽

Quantitative Polymerase Chain Reaction ◽

Hazard Ratio ◽

Histological Subtypes ◽

Mutational Status

ObjectiveThe tumor suppressor p53 generates the N-terminally truncated isoforms Δ40p53 and Δ133p53 that possess the ability to modulate p53 function in vitro. The aim of the present study was to evaluate the clinical relevance of p53 isoforms in the main histological subtypes of ovarian cancer.MethodsΔ40p53, Δ133p53, and full-length p53 (FLp53) expression was determined in 45 mucinous, 30 endometrioid, and 91 serous ovarian cancer specimens as well as 42 normal ovarian tissues using reverse transcriptase–quantitative polymerase chain reaction. In a subgroup of mucinous ovarian cancer cases, Δ40p53 expression was examined using Western blot analysis. A functional yeast-based assay and subsequent sequencing were performed to analyze the p53 mutational status.ResultsIn endometrioid cancer specimens, Δ133p53 expression was significantly lower than in mucinous and serous cases (P = 0.016) or in normal tissues (P = 0.004). Mucinous cancer samples showed elevated Δ40p53 expression as compared with normal ovarian tissues (P = 0.003). In addition, high Δ40p53 expression constituted an independent prognostic marker for recurrence-free but not for overall survival in patients with mucinous ovarian cancer (hazard ratio, 0.267; 95% confidence interval, 0.094–0.756 [P = 0.013]; hazard ratio, 0.453, 95% confidence interval, 0.193–1.064 [P = 0.069]). Western blot analysis confirmed the presence of p53β and Δ40p53α in a subset of patients with mucinous ovarian cancer. Expression of p53 isoforms was not associated with p53 mutational status or clinicopathologic parameters.ConclusionsWe show that expression of p53 isoforms differs in histological subtypes, thus supporting the hypothesis that histological subtypes represent distinct disease entities. In addition, we provide first evidence for a favorable role of Δ40p53 in patients with mucinous ovarian cancer.

Download Full-text